The products, namely MVR-EX104 (EX104 for alopecia) and MVR-EX105 (EX105 for localised fat accumulation), were designated following review by the International Cosmetic Ingredient Nomenclature Committee (INC).
As the universal “passport” for cosmetic and personal care ingredients, the International Nomenclature of Cosmetic Ingredients (INCI) is an internationally recognised system that provides a standardised way to name ingredients on product labels, ensuring consistency across brands, countries, and languages.
INCI standards cover major markets including the US, EU, Canada, China, Japan, and ASEAN countries.
This dual certification is said to solidify ImmVira’s leading position in engineered exosome technology, facilitate overseas market entry, and enhance consumer trust through INCI’s mandated ingredient transparency.
Utilising proprietary OVPENS technology, the company developed its engineered exosome portfolio, including MVR-EX103 for skin-related conditions (INCI name granted in April 2025), EX104, and EX105, for direct commercialisation with flexible registration pathways, targeting the “substantial opportunities” in the ageing market.
On the back of the INCI validation, ImmVira is accelerating development of a global health and wellness product matrix spanning skin health, hair management, and fat reduction, to introduce a new generation of home-use professional-grade bioactive solutions.
“From skin repair to hair regeneration and localised fat reduction, our OVPENS platform demonstrates sustainable capacity for breakthrough healthcare innovations. Leveraging precision-engineered design and targeted delivery of multiplex functional proteins, we maintain a strategically balanced portfolio that directly targets high-value, ageing-related market opportunities with strong business acumen.
“The platform’s inherent expandability allows us to rapidly develop new pipeline candidates to address specific needs, enabling novel treatment modalities that empower the public to achieve health and beauty,” Dr Zhou Guoying, CEO of ImmVira, stated.
Expediting commercialisation to fuel clinical therapies
Founded in 2015, ImmVira is focused on the discovery, development, manufacturing and commercialisation of novel oncolytic immunotherapies and engineered exosome treatments.
According to data cited by the Shenzhen-headquartered company, the global market value of alopecia treatment and localised fat accumulation management is projected to reach USD89.9bn and USD191.5bn respectively by 2033.
“Utilising engineered exosome that co-delivers multi-functional proteins with designed precise efficacy and enhanced skin penetration, EX104 and EX105 enable deep cellular-level modulation through non-invasive topical use, reshaping traditional treatment paradigms,” the firm said.
On the clinical therapeutic front, ImmVira has also capitalised on its expertise in biological engineering to pioneer the development of exosomes targeting chronic, hard-to-treat diseases, such as wound healing and pulmonary fibrosis, as well as other age-related conditions.
“These selected engineered exosome assets are being deliberately accelerated through strategic, differentiated regulatory pathways to enable expedited commercialisation and generate sustainable cash flows that will fuel our broader drug development efforts.”
